Prognostic parameters of luminal A and luminal B intrinsic breast cancer subtypes of Pakistani patients

Hashmi, Atif Ali; Aijaz, Saher; Khan, Saadia Mehmood; Mahboob, Raeesa; Irfan, Muhammad; Zafar, Narisa Iftikhar; Nisar, Mariam; Siddiqui, Maham; Edhi, Muhammad Muzzammil; Faridi, Naveen; Khan, Amir

doi:10.1186/s12957-017-1299-9

Cited by 97 publications

(95 citation statements)

References 32 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previous studies have demonstrated that the prognosis of breast cancer is closely associated with tumor state, luminal type and axillary lymph node metastasis ( 22 , 23 ). It was previously demonstrated that the prognosis of patients with luminal A type breast cancer was the superior to that of patients with luminal B type breast cancer, whereas patients with HER2-positive and triple-negative breast cancer had the worst prognosis ( 24 ).…”

Section: Discussionmentioning

confidence: 99%

Predictive value of T2‑weighted magnetic resonance imaging for the prognosis of patients with mass‑type breast cancer with peritumoral edema

Liang

et al. 2020

Oncol Lett

View full text Add to dashboard Cite

The aim of the present study was to investigate the role of edema surrounding breast cancer masses in the prognostic prediction of magnetic resonance imaging (MRI) T2-weighted fat suppression sequence. For this purpose, 80 patients with mass-type breast cancer underwent conventional plain breast MRI, dynamic contrast-enhanced (DCE)-MRI or diffusion-weighted MRI scan. The associations between edema around the mass on MRI T2 fat suppression sequence plain scan and tumor stage, pathological findings, immunohistochemical findings and axillary lymph node metastasis were analyzed. The results revealed the presence of edema around the mass on the MRI T2 fat suppression sequence plain scan in 35 patients. By contrast, there was no abnormal enhancement on the DCE-MRI, and the apparent diffusion coefficient value did not decrease in these areas. Compared with the remaining 45 patients, the 35 patients with peritumoral edema exhibited a higher tumor stage and a higher rate of axillary lymph node metastasis (all P<0.05). However, there was no significant difference in pathological classification or the expression of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 (as determined by immunohistochemistry) between the two groups. In total, 12 cases of tumor shrinkage during neoadjuvant chemotherapy were accompanied by an improvement in edema. Taken together, the findings of the present study indicated that the presence of edema around the mass on the MRI T2 fat suppression sequence may predict poor prognosis in patients with mass-type breast cancer. Furthermore, the improvement of the peritumoral edema post-neoadjuvant chemotherapy may also be a predictor of a more favorable prognosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Predictive value of T2‑weighted magnetic resonance imaging for the prognosis of patients with mass‑type breast cancer with peritumoral edema

Liang

et al. 2020

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…Epidemiological research has shown that about 70% of BRCA patients are [38]. Nevertheless, ER-positive BRCA still constitutes a more heterogeneous group for diagnosis and treatment [39,40]. For instance, according to the HER2 status and KI67 protein level, ER-positive BRCA also consists of two major subtypes, i.e., luminal A and luminal B, with luminal B tumors presenting a worse prognosis than luminal A subtype [35,40].…”

Section: Discussionmentioning

confidence: 99%

“…Nevertheless, ER-positive BRCA still constitutes a more heterogeneous group for diagnosis and treatment [39,40]. For instance, according to the HER2 status and KI67 protein level, ER-positive BRCA also consists of two major subtypes, i.e., luminal A and luminal B, with luminal B tumors presenting a worse prognosis than luminal A subtype [35,40]. Currently, accumulating evidence has shown that epigenetic modifications, in especial DNA methylation, play important roles in BRCA progression and present close associations with the BRCA heterogeneity [41,42].…”

Section: Discussionmentioning

confidence: 99%

Methylome and transcriptome analyses reveal insights into the epigenetic basis for the good survival of hypomethylated ER-positive breast cancer subtype

Chen

Zhang

et al. 2020

Clin Epigenet

View full text Add to dashboard Cite

Background: Breast cancer (BRCA) is a heterogeneous disease, characterized by different histopathological and clinical features and responses to various therapeutic measures. Despite the research progress of DNA methylation in classification and diagnosis of BRCA and the close relationship between DNA methylation and hormone receptor status, especially estrogen receptor (ER), the epigenetic mechanisms in various BRCA subtypes and the biomarkers associated with diagnostic characteristics of patients under specific hormone receptor status remain elusive. Results: In this study, we collected and analyzed methylation data from 785 invasive BRCA and 98 normal breast tissue samples from The Cancer Genome Atlas (TCGA) database. Consensus classification analysis revealed that ERpositive BRCA samples were constitutive of two distinct methylation subgroups; with the hypomethylated subgroup showing good survival probability. This finding was further supported by another cohort of ER-positive BRCA containing 30 subjects. Additionally, we identified 977 hypomethylated CpG loci showing significant associations with good survival probability in ER-positive BRCA. Genes with these loci were enriched in cancerrelated pathways (e.g., Wnt signaling pathway). Among them, the upregulated 47 genes were also in line with good survival probability of ER-positive BRCA, while they showed significantly negative correlations between their expression and methylation level of certain hypomethylated loci. Functional assay in numerous literatures provided further evidences supporting that some of the loci have close links with the modulation of tumor-suppressive mechanisms via regulation gene transcription (e.g., SFRP1 and WIF1). Conclusions: Our study identified a hypomethylated ER-positive BRCA subtype. Notably, this subgroup presented the best survival probability compared with the hypermethylated ER-positive and hypomethylated ER-negative BRCA subtypes. Specifically, we found that certain upregulated genes (e.g., SFRP1 and WIF1) have great potential to suppress the progression of ER-positive BRCA, concurrently exist negative correlations between their expression and methylation of corresponding hypomethylated CpG loci. Therefore, our study indicates that different epigenetic mechanisms likely exist in ER-positive BRCA and provides novel clinical biomarkers specific to ER-positive BRCA diagnosis and therapy.

show abstract

“…Knowing the prevalence of subtypes in one population can help plan a general therapeutic approach [ 16 ].…”

Section: Discussionmentioning

confidence: 99%

Presentation of the Molecular Subtypes of Breast Cancer Detected By Immunohistochemistry in Surgically Treated Patients

Кондов¹,

Milenkovikj²,

Кондов³

et al. 2018

Open Access Maced J Med Sci

View full text Add to dashboard Cite

INTRODUCTION:The detection of estrogen, progesterone and HER-2 neu receptors on the surface of the tumour cell is a significant prognostic factor, alone or in combination. The presence or absence of receptors on the surface of the tumour cell is associated with the conditional gene expression in the tumour cell itself. Based on these genetically determined expressions of the tumour cell, five molecular subtypes of breast cancer have been classified on the St. Gallen International Expert Consensus in 2011 that can be immunohistochemically detected, with each subtype manifesting certain prognosis and aggression.AIM:Analyzing the presentation of molecular subtypes of breast cancer that are immunohistochemically detected in surgically treated patients at the Clinic for Thoracic and Vascular Surgery.MATERIAL AND METHODS:We used the international classification on molecular subtypes of breast cancer which divides them into: Luminal A (ER+ and/or PR+, HER-2 negative, Ki-67 < 14%), Luminal B with HER-2 negative (ER+ and/or PR+, HER-2 negative, Ki-67 ≥ 14%), Luminal B with HER-2 positive (ER+ and/or PR+, HER-2+, any Ki-67), HER-2 enriched (ER-, PR-, HER-2+), and basal-like (triple negative) (ER-, PR-, HER-2 negative, CK5/6+ and/or EGFR+). A total of 290 patients, surgically treated for breast cancer, were analysed during 2014.RESULTS:In our analysis, we found that Luminal A was present in 77 (26.55%) patients, Luminal B HER-2 negative was present in 91 (31.38%) patients, Luminal B HER-2 positive was present in 70 (24.14%) patients, HER-2 enriched was present in 25 (8.62%) patients and basal-like (or triple negative) was present in 27 (9.31%) patients.CONCLUSION:Detecting the subtype of breast cancer is important for evaluating the prognosis of the disease, but also for determining and providing an adequate therapy. Therefore, determining the subtype of breast cancer is necessary for the routine histopathological assay.

show abstract

Prognostic parameters of luminal A and luminal B intrinsic breast cancer subtypes of Pakistani patients

Cited by 97 publications

References 32 publications

Predictive value of T2‑weighted magnetic resonance imaging for the prognosis of patients with mass‑type breast cancer with peritumoral edema

Predictive value of T2‑weighted magnetic resonance imaging for the prognosis of patients with mass‑type breast cancer with peritumoral edema

Methylome and transcriptome analyses reveal insights into the epigenetic basis for the good survival of hypomethylated ER-positive breast cancer subtype

Presentation of the Molecular Subtypes of Breast Cancer Detected By Immunohistochemistry in Surgically Treated Patients

Contact Info

Product

Resources

About